Regenerative Therapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
60
NCT05216562
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
Phase: Phase 2/3
Role: Lead Sponsor
Start: Jul 1, 2021
Completion: Dec 30, 2022
Loading map...